CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,369 enrolled
Drug / intervention
MEDI3250 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02269475
NCT02269475Phase 3Completed
CompareCT.gov

A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of MEDI3250 Compared to Placebo in Healthy Japanese Children Age 7 Years Through 18 Years

AstraZeneca·interventional·Posted Oct 21, 2014·Updated Apr 4, 2017

In Brief

A Phase 3 clinical trial evaluating MEDI3250 and Placebo for Healthy Japanese Children Age 7 Years Through 18 Years. Completed, enrolled 1,369 participants across 38 sites.

Detailed Summary

The study is designed to gather the efficacy, safety and tolerability data in Japanese children 7 to 18 years of age that would support approval of MEDI3250 in Japan.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Japanese Children Age 7 Years Through 18 Years
CountriesJapan
Collaborators--

Timeline

Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 21, 2014
Enrollment StartOct 1, 2014
Primary CompletionApr 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.7 years ago

Interventions

MEDI3250drug

MEDI3250

Placebodrug

Placebo